@article { author = {Yuanyuan, Gao and Xue, Yu and Yachao, Li and Xiao, Feng and Xu, Chen}, title = {Association between IL-18 -607 C/A Polymorphism and the Risk of Prostate Cancer: A Meta-Analysis of Case-Control Studies}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {20}, number = {6}, pages = {1595-1602}, year = {2019}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {10.31557/APJCP.2019.20.6.1595}, abstract = {Background: Accumulating evidence shows that cytokines play an important role in the proliferation of prostatecancer. This research is trying to determine that IL-18 -607 C/A polymorphism confers susceptibility to prostate cancer.Methods: Meta-analysis was used to collect data. The relevant studies were identified through a comprehensive searchfrom PubMed, Excerpta Medica Database (EMBASE), Web of Science, and Chinese Biomedical Literature Database(CBM) to obtain related studies published up to December 6, 2017. The association between interleukin (IL)-18 -607 C/Apolymorphism and prostate cancer risk was assessed by odds ratios (ORs) together with their 95% confidence intervals(CIs). Results: Nine case-control studies from 6 articles were eventually identified. In the overall population, there is asignificant association between IL-18 -607 C/A polymorphism and prostate cancer risk in recessive (CC versus CA/AA:OR = 0.20, 95% CI = 0.15-0.27, P = 0.000) or dominant (CC/CA versus AA:OR = 0.42, 95% CI = 0.30–0.57, P = 0.000)models. In the sub-group analysis according to ethnicity, for Asians, IL-18 -607 C/A polymorphism was significantlyassociated with prostate cancer in allele contrast (C versus. A: OR=0.82, 95%CI=0.70-0.97, P=0.019), homozygote(CC versus. AA: OR=0.68, 95%CI=0.50-0.92, P=0.013), recessive (CC versus. CA/AA: OR=0.19, 95%CI=0.13-0.27,P=0.000), and dominant (CC/CA versus. AA: OR=0.37, 95%CI=0.28-0.48, P=0.000) models, for Caucasians, IL-18-607 C/A polymorphism was significantly associated with prostate cancer risk in allele contrast (C versus. A: OR=1.27,95%CI=1.02-1.58, P=0.033), homozygote (CC versus. AA: OR=1.86, 95%CI=1.19-2.91, P=0.007) and recessive (CCversus. CA/AA: OR=0.25, 95%CI=0.19-0.33, P=0.000) models. Conclusion: This meta-analysis has shown that IL-18-607 C/A polymorphism contributes to a decreased risk of prostate cancer risk in the Asian population but an increasedrisk in the Caucasian population.}, keywords = {IL-18,Prostate Cancer,Polymorphism,Meta-analysis}, url = {https://journal.waocp.org/article_88622.html}, eprint = {https://journal.waocp.org/article_88622_c04fd00b2ba4cf91c7f1d29b8a4b7fa2.pdf} }